Protocol Ledger

NCT03559062 · Phase III · COMPLETED

A Study to Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 Through 11 Years With Cystic Fibrosis

Interventional Phase III clinical trial protocol NCT03559062 sponsored by Vertex Pharmaceuticals in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-05-17 Enrollment: 67 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03559062
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)67 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03559062
Protocol FieldVerified Registry Value
NCT IdentifierNCT03559062
Consolidated Lead SponsorVertex Pharmaceuticals
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment67 participants (ACTUAL)
Registered Start Date2018-05-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03559062
Hospital Research SiteLocationSite Profile
The Children's Hospital at WestmeadWestmead, AustraliaOpen Hospital Dossier ->
Universitaetsklinikum EssenEssen, GermanyOpen Hospital Dossier ->
Medizinische Hochschule HannoverHanover, GermanyOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Vertex Pharmaceuticals across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI